Abstract:Identification of factors associated with proliferation in the hepatocellular carcinoma (HCC) microenvironment aids in understanding the mechanisms of disease progression and provides druggable targets. Gene expression profiles of individual cells in HCC and para-carcinoma tissues can be effectively obtained using the single-cell RNA sequencing (scRNA-Seq) technique. Here, we aimed to identify proliferative hepatocytes from HCC and para-carcinoma tissues, detect differentially expressed genes between the two types of proliferative hepatocytes, and investigate their potential roles in aberrant proliferation. Two respective gene signatures for proliferative cells and hepatocytes were established and used to identify proliferative hepatocytes from HCC and para-carcinoma tissues based on scRNA-Seq data. Gene expression profiles between the two types of proliferative hepatocytes were compared. Overall, 40 genes were upregulated in proliferative hepatocytes from para-carcinoma tissue, whereas no upregulated genes were detected in those from HCC tissue. Twelve of the genes, including HAMP, were specifically expressed in the liver tissue. Based on previous reports, we found that HAMP modulates cell proliferation through interaction with its receptor SLC40A1. Comprehensive analysis of cells in HCC and para-carcinoma tissues revealed that: (1) HAMP is specifically expressed in hepatocytes and significantly downregulated in malignant hepatocytes; (2) a subset of macrophages expressing SLC40A1 and genes reacting to various infections is present in para-carcinoma but not in HCC tissue. We independently validated the findings with scRNA-Seq and large-scale tissue bulk RNA-Seq/microarray analyses. HAMP was significantly downregulated in malignant hepatocytes. In addition, a subset of macrophages expressing SLC40A1 and genes reacting to various infections was absent in HCC tissue. These findings support the involvement of HAMP-SLC40A1 signaling in aberrant hepatocyte proliferation in the HCC microenvironment. The collective data from our in silico analysis provide novel insights into the mechanisms underlying HCC progression and require further validation with wet laboratory experiments.

Single‐cell and spatial transcriptomics reveal apelin/APJ pathway's role in microvessel formation and tumour progression in hepatocellular carcinoma

In Silico Analysis Suggests Disruption of Interactions Between HAMP from Hepatocytes and SLC40A1 from Macrophages in Hepatocellular Carcinoma.

Apelin (APLN) is a biomarker contributing to the diagnosis and prognosis of hepatocellular carcinoma

APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.

Study Progression of Apelin/APJ Signaling and Apela in Different Types of Cancer

Impact of apolipoprotein A1 on tumor immune microenvironment, clinical prognosis and genomic landscape in hepatocellular carcinoma

Cancer apelin receptor suppresses vascular mimicry in malignant melanoma

Deciphering the influence of AP1M2 in modulating hepatocellular carcinoma growth and Mobility through JNK/ErK signaling pathway control

Roles of apelin/APJ system in cancer: Biomarker, predictor, and emerging therapeutic target

Multi-dimensional single-cell characterization revealed suppressive immune microenvironment in AFP-positive hepatocellular carcinoma

Apelin Enhances Biological Functions in Lung Cancer A549 Cells by Downregulating Exosomal Mir-15A-5p

Apelin/APJ signaling activates autophagy to promote human lung adenocarcinoma cell migration

Deregulated AJAP1/ Β -Catenin/zeb1 Signaling Promotes Hepatocellular Carcinoma Carcinogenesis and Metastasis

Apj(+) Vessels Drive Tumor Growth and Represent a Tractable Therapeutic Target

Apelin/APJ: Vascular Function Regulatory Factor and New Targets for Drug Treatment

An Angiogenic Gene Signature for Prediction of the Prognosis and Therapeutic Responses of Hepatocellular Carcinoma

Deregulated AJAP1/β-catenin/ZEB1 signaling promotes hepatocellular carcinoma carcinogenesis and metastasis.

Apelin/APJ System: A Novel Promising Therapy Target for Pathological Angiogenesis

Apelin/APJ signaling in hypoxia-related diseases

The Apelin/APLNR system modulates tumor immune response by reshaping the tumor microenvironment

The apelin‑apelin receptor signaling pathway in fibroblasts is involved in tumor growth via p53 expression of cancer cells